European CHMP recommends approval of licence extension of avatrombopag (Doptelet)

The licence extension is for treatment of primary chronic immune thrombocytopenia in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Source:

European Medicines Agency